Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-operative ctDNA monitoring in stage I colon cancer: A case report.
Alden SL, Dhani H, Palsuledesai CC, Krinshpun S, Jurdi A, Christenson E, Browner I, Rosner S. Alden SL, et al. Front Oncol. 2022 Dec 14;12:1074786. doi: 10.3389/fonc.2022.1074786. eCollection 2022. Front Oncol. 2022. PMID: 36591529 Free PMC article.
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Kao CJ, Charmsaz S, Alden SL, Brancati M, Li HL, Balaji A, Munjal K, Howe K, Mitchell S, Leatherman J, Griffin E, Nakazawa M, Tsai HL, Danilova L, Thoburn C, Gizzi J, Gross NE, Hernandez A, Coyne EM, Shin SM, Babu JS, Apostol GW, Durham J, Christmas BJ, Konig MF, Lipson EJ, Naidoo J, Cappelli LC, Pabani A, Ged Y, Baretti M, Brahmer J, Hoffman-Censits J, Seiwert TY, Garonce-Hediger R, Guha A, Bansal S, Tang L, Jaffee EM, Chandler GS, Mohindra R, Ho WJ, Yarchoan M. Kao CJ, et al. Among authors: alden sl. J Clin Invest. 2024 Aug 29;134(20):e176567. doi: 10.1172/JCI176567. J Clin Invest. 2024. PMID: 39403935 Free PMC article. Clinical Trial.
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
Alden SL, Charmsaz S, Li HL, Tsai HL, Danilova L, Munjal K, Brancati M, Warner A, Howe K, Griffin E, Nakazawa M, Thoburn C, Gizzi J, Hernandez A, Gross NE, Coyne EM, Hallab E, Shin SS, Durham J, Lipson EJ, Ged Y, Baretti M, Hoffman-Censits J, Seiwert TY, Guha A, Bansal S, Tang L, Chandler GS, Mohindra R, Garonce-Hediger R, Jaffee EM, Ho WJ, Kao C, Yarchoan M. Alden SL, et al. J Immunother Cancer. 2025 Jan 19;13(1):e009734. doi: 10.1136/jitc-2024-009734. J Immunother Cancer. 2025. PMID: 39832896
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.
Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, Pecci F, Lamberti G, Gandhi MM, Vaz VR, Spurr LF, Sholl LM, Pfaff KL, Rodig SJ, Li YY, Cherniack AD, Nishino M, Johnson BE, Awad MM. Di Federico A, et al. Among authors: alden sl. Ann Oncol. 2024 Oct;35(10):902-913. doi: 10.1016/j.annonc.2024.06.014. Epub 2024 Jun 29. Ann Oncol. 2024. PMID: 38950679
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Alessi JV, Ricciuti B, Alden SL, Bertram AA, Lin JJ, Sakhi M, Nishino M, Vaz VR, Lindsay J, Turner MM, Pfaff K, Sharma B, Felt KD, Rodig SJ, Gainor JF, Awad MM. Alessi JV, et al. Among authors: alden sl. J Immunother Cancer. 2021 Nov;9(11):e003536. doi: 10.1136/jitc-2021-003536. J Immunother Cancer. 2021. PMID: 34824161 Free PMC article.
16 results